Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects With Advanced Solid Malignancies

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE1

Total Enrollment

42 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-07-19

Study Completion Date

2024-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to determine to evaluate safety and tolerability of CPL304110 when administered once daily to adults with advanced solid malignancies.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study to Evaluate Maximum Tolerated Dose of Oral CB-03-10 With Dose Expansion Phase, in Advanced Solid Tumors

NCT03863145

Advanced Refractory Solid Tumors Subjects Considered Likely to Respond to CB-03-10

RECRUITING EARLY_PHASE1

SMP-3124LP in Adults With Advanced Solid Tumors

NCT06526819

Solid Tumor

RECRUITING PHASE1/PHASE2

Study to Evaluate Safety, Tolerability, Maximum Tolerated Dose (MTD), Efficacy, and Pharmacokinetics (PKs) of CPI-613 Given Twice Weekly for Three Consecutive Weeks in Patients With Advanced Hematologic Malignancies

NCT01034475

Advanced Hematologic Malignancies

COMPLETED PHASE1

A Study of CSCJC3456 in Patients With Advanced Malignant Tumors

NCT06717750

Advanced Malignant Solid Tumors

RECRUITING PHASE1

Ph. 1, Evaluation of Safety, Tolerability, PK, Anti-tumor Activity of STP707 IV in Subjects With Solid Tumors

NCT05037149

Solid Tumor

ACTIVE_NOT_RECRUITING PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

01FGFR2018 is an Open-label, Multicentre, Dose Escalation Study to Assess Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects with Advanced Solid Malignancies. The study consists of 3 parts: initial dose escalation (Part 1 - without FGFR, fibroblast growth factor receptor, molecular aberrations), dose escalation (Part 2 - with FGFR molecular aberrations) and dose extension (Part 3 - with FGFR molecular aberrations).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gastric Cancer Bladder Cancer Squamous Non-small Cell Lung Cancer Cholangiocarcinoma Sarcoma Endometrial Cancer Other Solid Tumours

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CPL304110

CPL304110 will be administered once daily to adults with advanced solid malignancies in 28-day cycles.

Group Type EXPERIMENTAL

CPL304110

Intervention Type DRUG

CPL304110 is to be administered orally as hard gelatine capsules once daily in 28-day cycles.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CPL304110

CPL304110 is to be administered orally as hard gelatine capsules once daily in 28-day cycles.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

PG19

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient or legal guardian, if permitted by local regulatory authorities, provides informed consent to participate in the study must be performed before any procedure's protocol related
* age of ≥25 years old
* Performance Score ≥70 in accordance with the Karnofsky Performance Score (KPS),
* life expectancy period of at least 3 months on the screening day,
* Have measurable disease according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)
* subject (or his/her partner) of childbearing potential willingness to use acceptable forms of contraception
* adequate blood, liver, renal and urine parameters
* phosphate levels within normal range
* HIV, HCV (hepatitis C virus) and HBV negative (hepatitis B virus),
* adequate cardiac function

Part 1

* Patients with histologically confirmed advanced gastric cancer, bladder cancer, squamous lung cancer or non-small cell lung cancer with squamous immunophenotype, cholangiocarcinoma, sarcoma or endometrial cancer, be refractory to prior therapies and without effective further treatment options.

Part 2 and 3

* Patients with histologically confirmed advanced gastric cancer, bladder cancer, squamous lung cancer or non-small cell lung cancer with squamous immunophenotype, be refractory to prior therapies and without effective further treatment options.
* Subject's archival formalin-fixed paraffin-embedded (FFPE) tumour sample available for molecular alteration diagnostics, and/or a possibility to collect a new biopsy.
* Present molecular alteration within FGFR 1, 2 or 3

Exclusion Criteria

* Any other current malignancy or malignancy diagnosed within the past five (5) years.
* Active brain metastases or leptomeningeal metastases.
* concurrent anticancer treatment within 28 days before the start of trial treatment; major surgery within 28 days before the start of trial treatment); use of blood transfusion within 7 days before the start of trial treatment,
* prior therapy with an agent directed to another FGFR inhibitor,
* pregnancy and/or breastfeeding,
* phosphate levels above the upper limit of normal,
* ectopic calcification/mineralization,
* endocrine alteration related to calcium/phosphate homeostasis e.g. parathyroid disorders, history of parathyroidectomy,
* concomitant therapies increasing calcium/phosphate serum levels,
* inability to take oral medicines,
* corneal disorder and/or keratopathy,
* persisting toxicity related to prior therapy Grade \> 1 CTCAE v5.0, except polyneuropathy and alopecia,
* clinically significant (i.e., active) cardiovascular disease. History of abdominal fistula, bowel obstruction (Grade IV), gastrointestinal perforation, intra-abdominal abscess within 6 months of enrollment. Other significant diseases, which, in the opinion of the investigator, might impair the subject's tolerance of trial treatment.
* Receipt of any organ transplantation including allogeneic stem-cell transplantation.

Part 2 and 3

* No FFPE tumour sample available to conduct FGFR alteration eligibility tests and no biopsy option.

Minimum Eligible Age

25 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No